These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7546657)

  • 1. Recombinant adenoviruses as vaccines.
    Randrianarison-Jewtoukoff V; Perricaudet M
    Biologicals; 1995 Jun; 23(2):145-57. PubMed ID: 7546657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational design of gene-based vaccines.
    Barouch DH
    J Pathol; 2006 Jan; 208(2):283-9. PubMed ID: 16362986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors.
    Seregin SS; Amalfitano A
    Expert Opin Biol Ther; 2009 Dec; 9(12):1521-31. PubMed ID: 19780714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered adenovirus serotypes for overcoming anti-vector immunity.
    Dharmapuri S; Peruzzi D; Aurisicchio L
    Expert Opin Biol Ther; 2009 Oct; 9(10):1279-87. PubMed ID: 19645630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenoviruses as vectors for HIV vaccines.
    Gómez-Román VR; Robert-Guroff M
    AIDS Rev; 2003; 5(3):178-85. PubMed ID: 14598567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fish vaccine antigens produced or delivered by recombinant DNA technologies.
    Leong JC; Anderson E; Bootland LM; Chiou PW; Johnson M; Kim C; Mourich D; Trobridge G
    Dev Biol Stand; 1997; 90():267-77. PubMed ID: 9270855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant ovine atadenovirus induces a strong and sustained T cell response against the hepatitis C virus NS3 antigen in mice.
    Wüest T; Both GW; Prince AM; Hofmann C; Löser P
    Vaccine; 2004 Jul; 22(21-22):2717-21. PubMed ID: 15246602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCG as a vector for the construction of multivalent recombinant vaccines.
    Gicquel B
    Biologicals; 1995 Jun; 23(2):113-8. PubMed ID: 7546653
    [No Abstract]   [Full Text] [Related]  

  • 9. Gene therapy progress and prospects: adenoviral vectors.
    St George JA
    Gene Ther; 2003 Jul; 10(14):1135-41. PubMed ID: 12833122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy.
    Kim J; Cho JY; Kim JH; Jung KC; Yun CO
    Cancer Gene Ther; 2002 Sep; 9(9):725-36. PubMed ID: 12189522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
    Roberts DM; Nanda A; Havenga MJ; Abbink P; Lynch DM; Ewald BA; Liu J; Thorner AR; Swanson PE; Gorgone DA; Lifton MA; Lemckert AA; Holterman L; Chen B; Dilraj A; Carville A; Mansfield KG; Goudsmit J; Barouch DH
    Nature; 2006 May; 441(7090):239-43. PubMed ID: 16625206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neonatal cotton rats do not exhibit destructive immune responses to adenoviral vectors.
    Zepeda M; Wilson JM
    Gene Ther; 1996 Nov; 3(11):973-9. PubMed ID: 8940637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances towards targetable adenovirus vectors for gene therapy.
    Einfeld DA; Roelvink PW
    Curr Opin Mol Ther; 2002 Oct; 4(5):444-51. PubMed ID: 12435045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New serotypes of adenoviral vectors.
    Stone D; Lieber A
    Curr Opin Mol Ther; 2006 Oct; 8(5):423-31. PubMed ID: 17078384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion.
    Schagen FH; Ossevoort M; Toes RE; Hoeben RC
    Crit Rev Oncol Hematol; 2004 Apr; 50(1):51-70. PubMed ID: 15094159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenovirus vector-mediated gene transfer into stem cells.
    Kawabata K; Sakurai F; Koizumi N; Hayakawa T; Mizuguchi H
    Mol Pharm; 2006; 3(2):95-103. PubMed ID: 16579638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
    Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
    Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Live viral vectors: construction of a replication-deficient recombinant adenovirus.
    Fooks AR
    Methods Mol Med; 2003; 87():37-50. PubMed ID: 12958448
    [No Abstract]   [Full Text] [Related]  

  • 19. [Significance of recombinant adenoviruses in experimental gene therapy].
    Adám E; Nász I
    Orv Hetil; 1995 Apr; 136(15):755-61. PubMed ID: 7724208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field.
    Majhen D; Calderon H; Chandra N; Fajardo CA; Rajan A; Alemany R; Custers J
    Hum Gene Ther; 2014 Apr; 25(4):301-17. PubMed ID: 24580050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.